Back to search

Article

Mitochondrial determinants of response and resistance to venetoclax <i>plus</i> cytarabine duplet therapy in acute myeloid leukemia

2020-08-17

Abstract excerpt

The development of resistance to conventional and targeted therapy represents a major clinical barrier in treatment of acute myeloid leukemia (AML). We show that the resistance to cytarabine (AraC) and its associated mitochondrial phenotype were reversed by genetic silencing or pharmacological inhibition of BCL2 in a caspase-dependent manner. BCL2-inhibitor venetoclax (VEN) enhancement of AraC efficacy was indepen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1fdc2779-f6b0-5fcd-b925-3ee8b06f0002
DOI
10.1101/2020.08.17.253856
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mitochondrial determinants of response and resistance to venetoclax <i>plus</i> cytarabine duplet therapy in acute myeloid leukemiaDOI 10.1101/2020.08.17.253856
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaSemantic proximity
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity
Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity
The Spectrum of Venetoclax-Based Treatments in Acute Myeloid LeukemiaSemantic proximity
<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity
Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity
Immune recovery in tumor microenvironment of<i>TP53</i>-mutated AML following venetoclax combination therapySemantic proximity
Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of ResistanceSemantic proximity
Select a neighboring publication to make it the new centre.